Rhythm Pharmaceuticals Inc.

2 days ago · seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2026 Earnings Call Transcript

2 days ago · marketbeat.com

Rhythm Pharmaceuticals NASDAQ: RYTM reported third-quarter global net product sales of $92.1 million, up 29% sequentially, as the company cited a strong early U.S. launch for IMCIVREE in acquired hypothalamic obesity, or acquired HO. The company also outlined plans to advance bivamelagon into Phase III studies for acquired HO and Prader-Willi syndrome, while expanding its international commercial footprint.

2 days ago · zacks.com

Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to a loss of $0.82 per share a year ago.

2 days ago · globenewswire.com

-- Strong U.S. launch momentum for IMCIVREE ® (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 -- -- Third quarter 2026 net product revenue from global sales of IMCIVREE of $92.1 million, an increase of 29% from the prior quarter -- -- Commercial launch of IMCIVREE in Japan for patients with acquired HO underway -- -- Bivamelagon to advance into pivotal development in Prader-Willi syndrome --

3 days ago · globenewswire.com

-- Amendment revised royalty structure from low-to-mid-single digits to 1% on global net sales of Rhythm MC4R agonists, including setmelanotide, bivamelagon and RM-718 -- -- Rhythm to pay LG Chem additional fixed payments totaling $350 million over four years --

10 days ago · zacks.com

Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

16 days ago · globenewswire.com

BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 3, 2026 to report its third quarter 2026 financial results and provide a corporate update.

23 days ago · zacks.com

Rhythm Pharmaceuticals (RYTM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

2 months ago · globenewswire.com

-- Real-world data showed reductions in BMI with up to 18 months of setmelanotide therapy in 30 paediatric patients with acquired hypothalamic obesity (HO) in France – -- Phase 3 analyses demonstrated improvements across multiple cardiometabolic risk indices with setmelanotide in acquired HO -- BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced Rhythm and its collaborators will present three posters and three oral presentations relating to the company's work in rare melanocortin-4 receptor (MC4R) pathway diseases at the 64th Annual European Society for Paediatric Endocrinology (ESPE) Meeting taking place September 8-10 in Marseille, France.